---
title: "Ozempic vs Wegovy: Same Drug, Different Doses (2026) | GLPMate"
url: https://glpmate.me/blog/ozempic-vs-wegovy-2026
language: en
description: "Ozempic vs Wegovy: the same semaglutide with different approved uses, doses and pens. Compare label doses, trial weight loss and what to ask your doctor."
updated: 2026-10-14
---
[Blog](/blog)

# Ozempic vs Wegovy: is Ozempic the same as Wegovy, and how do the doses and results differ?

By [the GLPMate team](/editorial-policy) · Based on FDA prescribing information & peer-reviewed sources · Updated 2026-10-14 · 6 min read

Quick answer

Ozempic and Wegovy contain the same medicine, semaglutide, but are approved for different things. Ozempic treats type 2 diabetes at up to 2 mg weekly; Wegovy is for weight loss, heart-risk reduction and MASH at 2.4 mg, with up to 7.2 mg for some adults. In STEP 2, people with diabetes lost 9.6% of body weight on 2.4 mg vs 7.0% on 1 mg. Which one fits is your prescriber's call.

## Is Ozempic the same as Wegovy?

Yes and no. **Ozempic** and **Wegovy** contain the same active ingredient, **semaglutide**, a GLP-1 receptor agonist made by Novo Nordisk. Both are injected once a week. But they are separate products with separate US labels, and that shapes who gets which one.

- **Ozempic** is a type 2 diabetes medicine. Its label covers blood sugar control, lowering the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes and heart disease, and slowing kidney decline in adults with type 2 diabetes and chronic kidney disease. Its label has no weight-management indication.
- **Wegovy** is approved for weight reduction in adults and teens aged 12 and over, for lowering heart risk in adults with established heart disease and overweight or obesity (diabetes not required), and for MASH with moderate to advanced liver fibrosis (an accelerated approval). The heart indication rests on the SELECT trial, where major cardiovascular events occurred in 6.5% of people on semaglutide 2.4 mg versus 8.0% on placebo over an average of about 40 months.

The other big difference is dose. Ozempic tops out at 2 mg a week. Wegovy’s usual maintenance dose is 2.4 mg, and the label now allows 7.2 mg for some adults.

## Ozempic vs Wegovy at a glance

Ozempic | Wegovy

**Active ingredient** | Semaglutide | Semaglutide

**Main US approvals** | Type 2 diabetes; heart-risk reduction in type 2 diabetes with heart disease; kidney protection in type 2 diabetes with CKD | Weight reduction (adults, ages 12+); heart-risk reduction with established heart disease and overweight/obesity; MASH (F2–F3)

**Starting dose** | 0.25 mg weekly for 4 weeks | 0.25 mg weekly for 4 weeks

**Dose steps** | 0.5 mg, then 1 mg and 2 mg only if more glucose lowering is needed | 0.5, 1 and 1.7 mg, each for 4 weeks

**Maintenance** | 0.5, 1 or 2 mg (1 mg for the kidney indication) | 2.4 mg (recommended) or 1.7 mg; 7.2 mg option for adult weight reduction

**Maximum** | 2 mg | 7.2 mg (adult weight reduction only)

**Injection devices** | Multi-dose pens (4 doses each), plus single-dose syringes | Single-dose pens and syringes, a 4-dose 2.4 mg FlexTouch pen, and a 7.2 mg single-dose pen (Wegovy HD)

**Tablet version** | Ozempic tablets, once daily (type 2 diabetes) | Wegovy tablets, once daily (weight, heart risk)

Both brands now have tablet versions in the US label. If you’re weighing a pill instead of a shot, see our [oral GLP-1 pills comparison](/blog/oral-glp-1-pills-compared-2026).

## How do Ozempic and Wegovy doses and titration differ?

Both labels start at 0.25 mg and step up no sooner than every 4 weeks, so the first month looks identical. After that, the goals differ:

- **Ozempic** moves to 0.5 mg. It only goes to 1 mg, and then 2 mg, if more glucose lowering is needed, each after at least 4 weeks on the current dose.
- **Wegovy** follows a fixed ladder (0.5 mg, then 1 mg, then 1.7 mg), reaching 2.4 mg or 1.7 mg from week 17. If a step isn’t tolerated, the label lets prescribers delay escalation by 4 weeks.
- **Wegovy 7.2 mg** is only for adults using it for weight reduction, after at least 4 weeks on 2.4 mg, when more weight loss is clinically indicated.

Our [GLP-1 dose escalation schedule](/blog/glp-1-dose-escalation-schedule-2026) sets out every step side by side, including tirzepatide.

## Does Ozempic cause as much weight loss as Wegovy?

The most useful evidence is **STEP 2**, because it tested both doses in the same trial. Adults with type 2 diabetes and overweight or obesity were randomly assigned to semaglutide 2.4 mg (the Wegovy dose), 1 mg (an Ozempic dose) or placebo for 68 weeks.

**−9.6% vs −7.0%** Average weight change after 68 weeks with semaglutide 2.4 mg versus 1 mg in STEP 2, in adults with type 2 diabetes (placebo: −3.4%). Same trial, same population; individual results vary.

Other trials fill in the picture. They were run in different people over different lengths of time, so read them separately:

- **Ozempic diabetes trials (label):** in a 30-week trial, average weight change was −3.8 kg on 0.5 mg and −4.7 kg on 1 mg, versus −1.2 kg on placebo. In a 40-week trial, 2 mg led to −6.4 kg versus −5.6 kg on 1 mg, a difference that wasn’t statistically significant.
- **STEP 1** (Wegovy 2.4 mg, adults without diabetes, 68 weeks): −14.9% versus −2.4% on placebo.
- **STEP UP** (adults without diabetes, 72 weeks): −18.7% on 7.2 mg versus −15.6% on 2.4 mg and −3.9% on placebo.

Average losses were smaller in the diabetes trials than in STEP 1, though those trials can’t be compared directly. Higher doses also brought more side effects (see below). If you want to see how semaglutide stacks up against tirzepatide, read [semaglutide vs tirzepatide](/blog/semaglutide-vs-tirzepatide-2026).

## Are the side effects of Ozempic and Wegovy different?

Same molecule, same warnings. Both labels carry the boxed warning about thyroid C-cell tumors in rodents, and both list pancreatitis, gallbladder problems, low blood sugar when combined with insulin or a sulfonylurea, kidney injury from dehydration and diabetic eye complications.

What changes is how often GI side effects show up, which tends to rise with dose:

- In **STEP 2**, GI adverse events were reported by 63.5% of people on 2.4 mg, 57.5% on 1 mg and 34.3% on placebo.
- In **STEP UP**, they were reported by 70.8% on 7.2 mg and 61.2% on 2.4 mg. Altered skin sensation (dysaesthesia) was also more common on 7.2 mg (22.9% vs 6.0%).
- The labels list nausea in 15.8–20.3% of people on Ozempic 0.5–1 mg in diabetes trials, and 44% on Wegovy 2.4 mg in weight trials. Those numbers come from different trials and populations.

## Why would a doctor prescribe Ozempic instead of Wegovy, or the other way round?

In practice the choice usually comes down to a few questions your prescriber weighs:

### What is it being prescribed for?

Type 2 diabetes points toward Ozempic, which also has a kidney indication. Weight reduction without diabetes, or heart disease with overweight or obesity but no diabetes, points toward Wegovy. Since Ozempic’s label has no weight-management indication, using it for weight alone would be off-label, a decision only a prescriber can make.

### How much dose room is needed?

Ozempic stops at 2 mg; Wegovy goes to 2.4 mg and, for some adults, 7.2 mg.

### What will be covered and supplied?

Insurance and reimbursement rules often depend on the indication. A plan may cover a diabetes medicine for diabetes but treat weight medicines differently. Rules vary by country and plan, so it’s worth checking early with your pharmacist or insurer.

## Can you switch from Ozempic to Wegovy?

People do switch between the two, but it should always be planned with your prescriber. A few points from the labels shape how it works:

- **Don’t take them together.** The Wegovy label says it isn’t recommended alongside other semaglutide-containing products or any other GLP-1 medicine.
- **There’s no label conversion.** The Wegovy label gives switching steps only between Wegovy injection and Wegovy tablets. Your prescriber decides which Wegovy step you start on and when.
- **New pens, new instructions.** The pens deliver different doses, and the Wegovy label asks for fresh training whenever the device changes. Never share pens.
- **Know your last dose.** Bring the date and dose of your last injection, plus any missed doses, to the appointment.

For the bigger picture, including switching between semaglutide and tirzepatide, see [switching GLP-1 medications](/blog/switching-glp-1-medications-2026).

## When should you call your doctor?

On either medicine, contact your care team promptly, or get urgent help, if you notice:

- Severe stomach pain that won’t go away, sometimes spreading to your back (possible pancreatitis)
- Pain in your upper stomach, fever, yellow skin or eyes, or clay-colored stools (possible gallbladder problems)
- Vomiting or diarrhea that stops you keeping fluids down, or dizziness and very little urine (possible dehydration)
- Swelling of the face, lips, tongue or throat, or trouble breathing (possible serious allergic reaction)
- Changes in your vision if you have type 2 diabetes
- Shakiness, sweating, confusion or other low blood sugar signs if you also take insulin or a sulfonylurea

## Tracking whichever one you take

Whether you’re on [Ozempic](/ozempic-tracker-app) or [Wegovy](/wegovy-tracker-app), GLPMate logs each dose with reminders, keeps a side-effect log with severity next to your weight trend, and builds a doctor report (PDF), useful if you and your prescriber are discussing a dose change or a switch.

This article is educational only and not medical advice. Talk to your prescriber before starting, switching or changing the dose of any semaglutide medicine.

FAQ

## FAQ

### Is Ozempic the same as Wegovy?

They contain the same active ingredient, semaglutide, and both are once-weekly injections from Novo Nordisk. They are approved for different uses, though: Ozempic for type 2 diabetes, and Wegovy for weight reduction, heart-risk reduction and MASH. Wegovy also goes to higher doses and comes in different pens.

### What is the difference between the Ozempic and Wegovy doses?

Both start at 0.25 mg weekly for 4 weeks. Ozempic's maintenance doses are 0.5, 1 or 2 mg, with 2 mg as the maximum. Wegovy steps up to 1.7 mg and then 2.4 mg (or 1.7 mg), and adults using it for weight reduction may go to 7.2 mg after at least 4 weeks on 2.4 mg if more weight loss is clinically indicated.

### Does Ozempic cause as much weight loss as Wegovy?

Ozempic isn't approved for weight management, and its doses stop at 2 mg. In STEP 2, adults with type 2 diabetes lost an average of 7.0% of body weight on semaglutide 1 mg (an Ozempic dose) versus 9.6% on 2.4 mg (the Wegovy dose) over 68 weeks. Individual results vary.

### Can I switch from Ozempic to Wegovy?

Switching is possible, but the Wegovy label doesn't set out a conversion from Ozempic, so your prescriber picks the starting dose and timing. The two shouldn't be used together, and the pens deliver different doses, so a switch usually means new pens and new instructions. Don't make the change on your own.

## Sources

1. FDA Prescribing Information — Ozempic (semaglutide) injection, DailyMed (revised 5/2026, checked 14 Oct 2026) — type 2 diabetes, heart and kidney indications; 0.25 mg start, 0.5/1/2 mg maintenance, 2 mg maximum; multi-dose pens and single-dose syringes; body-weight results from diabetes trials incl. 2 mg vs 1 mg; nausea 15.8–20.3% vs 6.1% placebo
2. FDA Prescribing Information — Wegovy (semaglutide) injection and tablets, DailyMed (revised 6/2026, checked 14 Oct 2026) — weight (adults and ages 12+), heart-risk and MASH indications; 0.25→1.7 mg steps, 1.7 or 2.4 mg maintenance, 7.2 mg for adult weight reduction; pens, FlexTouch and Wegovy HD; not recommended with other semaglutide products; nausea 44% vs 16% placebo
3. FDA Prescribing Information — Ozempic tablets and Rybelsus (oral semaglutide), DailyMed (revised 1/2026, checked 14 Oct 2026) — Ozempic tablets 1.5, 4 and 9 mg once daily for type 2 diabetes
4. Davies et al., Lancet 2021 (STEP 2) — semaglutide 2.4 mg vs 1.0 mg vs placebo in adults with overweight/obesity and type 2 diabetes, 68 weeks — −9.6% (2.4 mg) vs −3.4% (placebo); GI adverse events 63.5%, 57.5% and 34.3%
5. EASD e-Learning news — “STEP 2 does it again” (summary of STEP 2 results) — −7.0% mean weight change with semaglutide 1.0 mg at week 68
6. Wilding et al., NEJM 2021 (STEP 1) — semaglutide 2.4 mg vs placebo, 68 weeks — −14.9% vs −2.4% mean weight change in adults without diabetes
7. Wharton et al., Lancet Diabetes Endocrinol 2025 (STEP UP) — semaglutide 7.2 mg vs 2.4 mg vs placebo, 72 weeks — −18.7% vs −15.6% vs −3.9%; GI events 70.8% vs 61.2% vs 42.8%; dysaesthesia 22.9% vs 6.0%
8. Lincoff et al., NEJM 2023 (SELECT) — semaglutide 2.4 mg vs placebo in 17,604 adults with heart disease and overweight/obesity, no diabetes — major cardiovascular events 6.5% vs 8.0% (hazard ratio 0.80)

Sources checked: October 14, 2026

This article is educational and is not medical advice, diagnosis or treatment. Medication decisions — including dose changes and what to do after a missed dose — belong with your prescriber. If you experience severe symptoms, seek medical care.

## Keep reading

[GLP-1 dose escalation schedules ](/blog/glp-1-dose-escalation-schedule-2026)[Switching GLP-1 medications ](/blog/switching-glp-1-medications-2026)[Semaglutide vs tirzepatide ](/blog/semaglutide-vs-tirzepatide-2026)

## Start your GLP-1 journey with a companion that listens.

Free to start. iOS & Android.

[ Download on the **App Store** ](https://glpmate.go.link?adj_t=22klhq12&adj_campaign=blog-ozempic-vs-wegovy-2026&adj_redirect_android=https%3A%2F%2Fapps.apple.com%2Fapp%2Fid6788548235&adj_redirect_macos=https%3A%2F%2Fapps.apple.com%2Fapp%2Fid6788548235&adj_redirect_windows=https%3A%2F%2Fapps.apple.com%2Fapp%2Fid6788548235) [ GET IT ON **Google Play** ](https://glpmate.go.link?adj_t=22klhq12&adj_campaign=blog-ozempic-vs-wegovy-2026&adj_redirect_ios=https%3A%2F%2Fplay.google.com%2Fstore%2Fapps%2Fdetails%3Fid%3Dapp.eleutheromania.glpmate&adj_redirect_macos=https%3A%2F%2Fplay.google.com%2Fstore%2Fapps%2Fdetails%3Fid%3Dapp.eleutheromania.glpmate&adj_redirect_windows=https%3A%2F%2Fplay.google.com%2Fstore%2Fapps%2Fdetails%3Fid%3Dapp.eleutheromania.glpmate)